SUPERNUS PHARMACEUTICALS, INC. financials

SUPN CIK 0001356576

Source: EDGAR filings · Built 2026-06-02T04:07:27Z

Key metrics by reporting period

Up to six most-recent periods side-by-side. Rows are the curated key lines — revenue, margins, cash, debt, equity, cash-flow totals, plus the derived and valuation metrics we compute on top. For every tag a filer reported in one period, use the single-filing drilldown below.

Derived Metrics

Concept FY 2025FY 2024FY 2024FY 2022FY 2021FY 2020
Free Cash Flow 45.99M 171.23M 110.53M 116.41M 134.15M
EBITDA 29.28M 162.08M 79.59M 131.67M 118.62M 191.84M
Working Capital 306.01M 393.67M 202.92M 46.19M 286.21M 385.31M
Net Debt -87.47M -35.06M -33.53M 351.64M 223.59M 129.45M
Gross Margin 89.63% 88.23% 86.21% 86.93% 89.92%
Operating Margin -8.66% 12.34% -0.87% 6.91% 14.84% 33.38%
Net Margin -5.36% 11.16% 0.22% 9.10% 9.21% 24.39%
Return on Equity (ROE) -3.63% 7.13% 0.14% 6.85% 6.55% 17.04%
Return on Assets (ROA) -2.65% 5.40% 0.10% 3.57% 3.16% 8.44%
Current Ratio 1.90× 2.35× 1.70× 1.07× 1.91× 2.57×
Debt-to-Equity 0.04× 0.03× 0.05× 0.50× 0.52× 0.56×
Effective Tax Rate 21.37% 24.53% 52.47% 0.05% 26.99% 24.72%
Cash Conversion Ratio -1.23× 2.33× 84.41× 1.92× 2.38× 1.09×
Accruals Ratio -0.06× -0.07× -0.09× -0.03× -0.04× -0.01×
SBC % of Revenue 4.60% 4.19% 4.40% 2.63% 3.09% 3.18%
CapEx Coverage 35.37× 237.17× 201.61× 283.56× 32.56×
Free Cash Flow Per Share $0.81 $3.06 $1.99 $1.89 $2.50

Valuation Metrics

Concept FY 2025FY 2024FY 2024FY 2022FY 2021FY 2020
P/E Trailing (Diluted) 27.39× 1447.00× 34.30× 29.76× 10.66×
P/FCF 61.00× 11.82× 14.53× 18.90× 10.07×
FCF Yield 1.64% 8.46% 6.88% 5.29% 9.93%
EV / EBITDA 94.54× 12.22× 19.48× 17.37× 14.98× 7.61×
P/S 3.97× 3.05× 2.61× 2.90× 2.68× 2.56×
P/B 2.69× 1.95× 1.72× 2.18× 1.90× 1.79×

Income Statement

Concept FY 2025FY 2024FY 2024FY 2022FY 2021FY 2020
Revenue from Contract with Customer, Excluding Assessed Tax 718.95M 661.82M 607.52M 667.24M 579.77M 520.40M
Cost of Goods and Services Sold 74.56M 77.91M 83.78M 87.22M 52.46M
Research and Development Expense 106.23M 108.80M 91.59M 74.55M 90.47M 75.96M
Selling, General and Administrative Expense 485.56M 321.58M 336.36M 377.22M 304.76M 200.68M
Operating Income (Loss) -62.28M 81.67M -5.27M 46.12M 86.03M 173.70M
Income Tax Expense (Benefit) -10.48M 24.00M 1.45M 32.00K 19.75M 41.70M
Net Income (Loss) Attributable to Parent -38.55M 73.86M 1.32M 60.71M 53.42M 126.95M
Earnings Per Share, Basic $-0.68 $1.34 $0.02 $1.13 $1.01 $2.41
Weighted Average Number of Shares Outstanding, Basic 56.45M 55.10M 54.54M 53.67M 53.10M 52.62M
Earnings Per Share, Diluted $-0.68 $1.32 $0.02 $1.04 $0.98 $2.36
Weighted Average Number of Shares Outstanding, Diluted 56.45M 55.96M 55.51M 61.68M 54.36M 53.69M

Balance Sheet

Concept FY 2025FY 2024FY 2024FY 2022FY 2021FY 2020
Cash and Cash Equivalents, at Carrying Value 128.45M 69.33M 75.05M 93.12M 203.43M 288.64M
Assets, Current 644.18M 686.07M 493.11M 734.15M 601.59M 630.42M
Assets 1.45B 1.37B 1.28B 1.70B 1.69B 1.50B
Liabilities, Current 338.17M 292.40M 290.20M 687.96M 315.38M 245.11M
Long-term Debt, Excluding Current Maturities 379.25M
Liabilities 390.93M 332.34M 356.16M 816.30M 873.30M 759.24M
Stockholders' Equity Attributable to Parent 1.06B 1.04B 921.52M 886.20M 815.85M 744.86M
Common Stock, Shares, Outstanding 57.46M 55.74M 54.72M 54.25M 53.26M 52.87M

Cash Flow Statement

Concept FY 2025FY 2024FY 2024FY 2022FY 2021FY 2020
Net Cash Provided by (Used in) Operating Activities 47.33M 171.95M 111.08M 116.83M 127.13M 138.40M
Payments to Acquire Property, Plant, and Equipment 1.34M 725.00K 551.00K 412.00K 3.45M
Net Cash Provided by (Used in) Investing Activities 4.11M -189.87M 268.73M -216.66M -81.91M -34.70M
Net Cash Provided by (Used in) Financing Activities 9.13M 12.19M -397.88M -10.48M -130.42M 3.56M

Raw XBRL tagging for a single filing

Every us-gaap and custom concept the filer tagged for one fiscal period, grouped by statement. Start here when a number in the trend table above surprises you and you want to see the exact tag behind it. Derived and valuation rows are omitted here because they already appear in the trend table.

Most recent filing shown by default.

Compare filings side-by-side

Diff any two filings with deltas and added / removed tags.

Immaterial rows are USD line items under 1% of the period's revenue — the noise floor below which a single tag rarely moves the investment thesis. Revenue is read from the filer's top-line concept (Revenues / RevenueFromContractWithCustomerExcludingAssessedTax, with a fallback chain). Non-USD rows, rows without a numeric value, and every row on a filing with no identifiable revenue anchor stay visible. Flip the switch off to see every tag the filer reported for the period.

Loading filing details…

Methodology

All facts on this page come straight from SEC EDGAR XBRL company-facts filings (SUPN CIK 0001356576), grouped by financial statement using FASB's base us-gaap presentation taxonomy. Filers may re-parent concepts onto different statements in their own extension taxonomy, so a handful of rows can show up under a different statement than on the actual 10-K / 10-Q; custom concepts and any we couldn't map fall into Other. Hover a cell to see the fully-qualified concept name and the filer's description.

For the full methodology — statement grouping, the Other bucket, derived metrics, and fact tooltips — see the methodology reference for the statement grouping, the "Other" bucket, derived metrics, and fact tooltips.

Related tickers

DXC

DXC TECHNOLOGY CO

NHI

National Health Investors, Inc.

VTGN

Vistagen Therapeutics, Inc.